Amoxicillin For Suspension
NDC Package 81964-207-52

11-digit billing NDC: 81964020752 · Billing unit: ML · 100 ML per package

Package Information

Amoxicillin for suspensions is adults and Pediatric PatientsUpper Respiratory Tract Infectionsofthe Ear, Nose, and Throat:Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcusspecies. This formulation utilizes a for suspension delivery system. Marketed by Usantibiotics, Llc, this product is identified by NDC 81964-207 and is authorized under FDA application NDA050760.

Identification & Billing

NDC Package Code
81964-207-52
Package Description
100 mL in 1 BOTTLE
Product Code
11-Digit Billing Format
81964020752
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
Units Per Package
100 ML
RxNorm Crosswalk
  • RxCUI: 308189 - amoxicillin 400 MG in 5 mL Oral Suspension
  • RxCUI: 308189 - amoxicillin 80 MG/ML Oral Suspension
  • RxCUI: 308189 - amoxicillin (as amoxicillin trihydrate) 400 MG per 5 ML Oral Suspension

Clinical Specifications

Proprietary Name
Amoxicillin
Non-Proprietary Name
Amoxicillin
Substance Name
Amoxicillin
Dosage Form
For Suspension - A product, usually a solid, intended for suspension prior to administration.
Administration Route
Oral - Administration to or by way of the mouth.
Active Ingredient(s)
Usage Information
Adults and Pediatric PatientsUpper Respiratory Tract Infectionsofthe Ear, Nose, and Throat:Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcusspecies. (α-and ​​β-hemolytic isolates only), Streptococcus pneumoniae, Staphylococcusspp., or Haemophilus influenzae. InfectionsoftheGenitourinaryTract: Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis. Infectionsofthe Skin and Skin Structure:Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcusspp. (α-and ​β-hemolytic isolates only), Staphylococcusspp., or E. coli. Infectionsofthe Lower Respiratory Tract:Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcusspp. (α-and β-hemolytic isolates only), S. pneumoniae, Staphylococcusspp., or H. influenzae. Adults Patients onlyHelicobacter pyloriInfection and Duodenal Ulcer Disease : Triple therapy for Helicobacter pylori (H. pylori)with clarithromycin and lansoprazole : Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pyloriinfection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylorihas been shown to reduce the risk of duodenal ulcer recurrence. Dual therapy for H. pyloriwith lansoprazole : Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pyloriinfection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylorihas been shown to reduce the risk of duodenal ulcer recurrence. UsageTo reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxicillin and other antibacterial drugs, Amoxicillin should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Regulatory & Marketing

Labeler Name
Usantibiotics, Llc
Product Type
Human Prescription Drug
FDA Application #
NDA050760
Marketing Category
NDA AUTHORIZED GENERIC - A product marketed as a "generic" drug under an approved New Drug Application (NDA), rather than an Abbreviated New Drug Application (ANDA),.
Start Marketing Date
04-01-2024
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (81964-207). Click a package code to view its specific billing and regulatory data.

50 mL in 1 BOTTLE
75 mL in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 81964-207-52 identifies a specific commercial package of 100 ml in 1 bottle of Amoxicillin, a human prescription drug labeled by Usantibiotics, Llc. This for suspension is formulated for oral use and contains amoxicillin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Usantibiotics, Llc on April 01, 2024. The current certification is valid through December 31, 2027.

How is this Usantibiotics, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 81964020752. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
81964-207-52
11-Digit CMS (5-4-2)
81964-0207-52

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.